Global dementia cases projected to more than double by 2050
The annual incidence of new dementia cases globally is projected to rise from 11.4m in 2023 to 24.7m in 2050.
The annual incidence of new dementia cases globally will more than double, from 11.4m in 2023 to 24.7m in 2050. This increase is projected because life expectancy has gone up in recent decades, meaning more people are entering the age brackets in which dementia is most common.
In the United States, the number of adults diagnosed with dementia each year will increase from 514,000 in 2020 to 1m by 2060. The country faces a shortage of geriatric specialists, as the number of geriatricians in the US fell from 10,270 in 2000 to 7,413 in 2022.
The healthcare system faces strain from funding cuts, including Donald Trump’s One Big Beautiful Bill Act, which passed in 2025 and included nearly $1tn in cuts to Medicaid spending over 10 years. Medicaid pays for more than half of what the country spends on long-term care, making it a challenge for those eligible to get services like home care and personal care aid.
Labor shortages affect care provision, with the need for nursing assistants and home health aides expected to increase by 48% and 42% between 2020 and 2035. In May 2025, the median wage for nursing assistants at assisted living facilities and in home healthcare was less than $19 an hour, while the median wage for home health aides was $17 an hour.
The Food and Drug Administration has approved two drugs, Kisunla and Leqembi, that can modestly slow cognitive decline among some patients with early Alzheimer’s disease. The agency has also recently approved blood tests that can help diagnose the disease and perhaps predict if people are likely to develop it.
Key facts
- Global annual dementia incidence is projected to rise from 11.4m in 2023 to 24.7m in 2050.
- The number of geriatricians in the US decreased from 10,270 in 2000 to 7,413 in 2022.
- The One Big Beautiful Bill Act passed in 2025 and included nearly $1tn in cuts to Medicaid spending over 10 years.
Three perspectives
Neutral
Rising life expectancy is driving a projected increase in the number of people living with dementia globally.
Positive
The FDA has approved two drugs to slow cognitive decline and blood tests to help diagnose Alzheimer's.
Negative
The US healthcare system faces specialist shortages and significant Medicaid funding cuts.
Your week in news, every Wednesday
The biggest stories of the week for your edition, in your inbox every Wednesday morning, your time. Free, and you can unsubscribe at any time.